Bold Therapeutics is a biotechnology company developing cancer therapy for the treatment of gastric, pancreatic, colorectal, and other cancers. It offers BOLD-100, a ruthenium-based small molecule therapeutic, that enhances the activity of a range of other anti-cancer therapies by disabling a critical and previously untargeted cancer resistance, survival, and proliferation pathway.